NEW YORK--(BUSINESS WIRE)--DellaCamera Capital Management, LLC (“DellaCamera”) and related entities, which beneficially hold approximately 8.3% of the shares of Enzon Pharmaceuticals, Inc. (“Enzon” or the “Company”) (NASDAQ: ENZN), today announced that it formally requested on July 7, 2009 that Enzon’s Board of Directors set a record date in order to determine which stockholders are entitled to act by written consent. DellaCamera is pursuing a consent solicitation in order to amend Enzon’s By-laws and to remove Enzon CEO and President Jeffery H. Buchalter.
